Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anticoagulant treatment of rats with Walker 256 carcinosarcoma.

Literature DB >> 7130245

Anticoagulant treatment of rats with Walker 256 carcinosarcoma.

Abstract

Various anticoagulant, antiplatelet, and fibrinolytic agents have been found to be effective in reducing metastatic growth of experimental animal tumors. This effectiveness is attributed to the requirement for hemostatic factors in the implantation and growth of metastases. However, clotting and platelet factors are also present at the site of a primary tumor, the Walker 256 carcinosarcoma. Yet maximally tolerated doses of heparin or warfarin did not affect the primary growth of this rat tumor.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1982 PMID： 7130245 DOI： 10.1007/bf00402067

Source DB: PubMed Journal: J Cancer Res Clin Oncol ISSN： 0171-5216 Impact factor: 4.553

6 in total

1. Effect of Walker 256 tumor or turpentine on hemostatic factors locally and generally in rats.

Authors: C A Owen
Journal: Eur J Cancer Clin Oncol Date: 1981-08

2. Hypersensitivity to warfarin in rats with Walker 256 carcinoma.

Authors: C A Owen
Journal: Proc Soc Exp Biol Med Date: 1982-01

3. Platelet aggregation inhibitors in the prevention of metastasis in neoplastic disease: a review of experimental and clinical investigations.

Authors: H Gastpar; J L Ambrus; C M Ambrus
Journal: J Med Date: 1981

4. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75.

Authors: L R Zacharski; W G Henderson; F R Rickles; W B Forman; C J Cornell; R J Forcier; R Edwards; E Headley; S H Kim; J R O'Donnell; R O'Dell; K Tornyos; H C Kwaan
Journal: JAMA Date: 1981-02-27 Impact factor: 56.272

Review 5. Rationale and experimental design for the VA Cooperative Study of Anticoagulation (Warfarin) in the Treatment of Cancer.

Authors: L R Zacharski; W G Henderson; F R Rickles; W B Forman; C J Cornell; R J Forcier; H W Harrower; R O Johnson
Journal: Cancer Date: 1979-08 Impact factor: 6.860

6. The response of serum ceruloplasmin to injections of walker 256 tumor cells or turpentine into rats.

Authors: C A Owen
Journal: Biol Trace Elem Res Date: 1981-09 Impact factor: 3.738

6 in total

4 in total

Anticoagulant treatment of rats with Walker 256 carcinosarcoma.

1. Effect of Walker 256 tumor or turpentine on hemostatic factors locally and generally in rats.

2. Hypersensitivity to warfarin in rats with Walker 256 carcinoma.

3. Platelet aggregation inhibitors in the prevention of metastasis in neoplastic disease: a review of experimental and clinical investigations.

4. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75.

Review 5. Rationale and experimental design for the VA Cooperative Study of Anticoagulation (Warfarin) in the Treatment of Cancer.

6. The response of serum ceruloplasmin to injections of walker 256 tumor cells or turpentine into rats.

1. Antimetastatic effect of bromelain with or without its proteolytic and anticoagulant activity.

Review 2. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival.

3. Antiangiogenic activity of orally absorbable heparin derivative in different types of cancer cells.

4. Can LMWH improve the outcome of patients with inoperable stage III non-small cell lung cancer?